factor VIII

(redirected from Von Willebrand factor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

factor VIII

[′fak·tər ′āt]

(biochemistry)

Mentioned in ?

References in periodicals archive ?

Von Willebrand factor collagen binding activity in diagnosis of von Willebrand disease: an alternative to ristocetin cofactor activity?

Performance and clinical utility of a commercial von Willebrand factor collagen binding assay for laboratory diagnosis of Von Willebrand disease

Recombinant human von Willebrand factor (rhVWF): first-in-human study evaluating pharmacokinetics, demonstrating safety and tolerability in type 3 von Willebrand disease.

Baxter Presents Interim Phase 1 Safety and Tolerability Data at American Society of Hematology Meeting for Its Investigational Treatment for von Willebrand Disease

This means that all of the reagents necessary to test for the presence of von Willebrand Factor are available from Bio/Data," said Eugene J.

Bio/Data Corporation Releases New Control Plasma for vW Testing

Human coagulation factor VIII and von Willebrand factor VIII and 190 iu 250U von Willebrand factor

Framework Agreement Bleeding

does not contain von Willebrand factor, and, therefore, is not indicated in von Willebrand's disease.

Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A

Contract award: the concentrate of human coagulation factor viii containing von willebrand factor in the treatment of von willebrand disease.

Medicinal products for the blood and blood-forming organs

VWD is caused by a lack of working von Willebrand factor (VWF), a protein in the blood that is necessary for clotting.

Young Women Urged to Recognize Symptoms of Widely Undiagnosed Bleeding Disorder

Occlusin(TM) Injection is a novel product consisting of deformable particles that, through the action of von Willebrand factor (VWF) bound to the particle fibres, capture and activate platelets at the site of delivery leading to localized clot formation.

ViRexx Receives Approval for Phase I Clinical Trial

Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD).

United States : FDA approves first recombinant von Willebrand factor to treat bleeding episodes

Mannucci, from the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center of Milan (Italy), the treatment of severe hemophilia A with recombinant factor VIII (rFVIII) is associated with an 87% higher incidence of inhibitors than treatment with plasma-derived factor VIII containing von Willebrand factor (pdFVIII/VWF).

An international randomized controlled study reports a higher incidence of inhibitors with recombinant factor VIII than plasma-derived factor VIII containing von Willebrand factor in previously untreated patients with hemophilia A

An EIA for the quantification of human von Willebrand factor antigen in plasma.

Ramco Laboratories, Inc

Von Willebrand Factor (VWF) is a polymeric plasma glycoprotein comprising multiple 250-kDa subunits that facilitates platelet adhesion to the vessel wall by linking platelet membrane receptors to the subendothelium and is the cornerstone of platelet--endothelial interaction.

DDAVP might reduce the risk of Preeclampsia in pregnant women with VWF deficiency / DDAVP VWF Eksikligi olan Gebelerde Preeklampsi Riskini Azaltabilir